Drug Trial Radar · NCT06520488
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
118
Planned (sponsor's estimate)
Start
Aug 9, 2024
Primary completion
Mar 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and preliminary efficacy of HRS-4642 in combination with antineoplastic agents in subjects with advanced solid tumors with KRAS G12D mutations, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).
Conditions
- Advanced Solid Tumors
Interventions
HRS-4642Drug
Treatment group Part I: HRS-4642 combined with SHR-A1921 Treatment group Part II: HRS-4642 combined with SHR-A1904 Treatment group Part II: HRS-4642 combined with AG
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: (IB Period):DLTsTime frame: Within 28 days of the first dose
- Stage 1: (IB Period): adverse events (AEs)Time frame: Within 28 days of the first dos,About 1 year
- Phase II: (Phase II):investigator-assessed ORRTime frame: Assessed every 6 weeks,About 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.